Ieq Capital LLC Makes New Investment in Turn Therapeutics Inc. $TTRX

Ieq Capital LLC acquired a new stake in shares of Turn Therapeutics Inc. (NASDAQ:TTRX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 227,396 shares of the company’s stock, valued at approximately $1,660,000. Ieq Capital LLC owned 0.76% of Turn Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in TTRX. Hodges Capital Management Inc. bought a new position in Turn Therapeutics during the 4th quarter valued at about $39,000. LPL Financial LLC bought a new stake in Turn Therapeutics during the fourth quarter worth about $51,000. Tamar Securities LLC bought a new stake in Turn Therapeutics during the fourth quarter worth about $59,000. Composition Wealth LLC acquired a new stake in shares of Turn Therapeutics during the fourth quarter worth approximately $63,000. Finally, Geode Capital Management LLC bought a new position in shares of Turn Therapeutics in the fourth quarter valued at approximately $68,000.

Turn Therapeutics Price Performance

Shares of TTRX stock opened at $9.73 on Wednesday. Turn Therapeutics Inc. has a 1 year low of $2.57 and a 1 year high of $26.50. The firm’s 50 day moving average is $8.59 and its 200-day moving average is $5.61. The firm has a market capitalization of $289.84 million and a price-to-earnings ratio of -33.55. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Sell-side analysts forecast that Turn Therapeutics Inc. will post -0.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Zacks Research raised Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. Weiss Ratings cut Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Finally, Wall Street Zen upgraded Turn Therapeutics to a “hold” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Turn Therapeutics Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.